---
schema_version: "secwatch.filing_event.v1"
accession: "0001944048-24-000136"
form_type: "8-K"
ticker: "KVUE"
cik: "0001944048"
company_name: "Kenvue Inc."
filed_at: "2024-08-06T23:59:59+00:00"
generated_at: "2026-05-31T12:41:56.630940+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Kenvue Q2 adjusted EPS $0.32, organic sales +1.5%; reaffirms FY24 outlook

## Summary
- Net sales $4.0B, down 0.3% YoY; organic growth +1.5% (value realization +2.1%, volume -0.6%).
- Diluted EPS $0.03; adjusted diluted EPS $0.32 vs $0.31 prior year; adjusted operating margin 22.8% vs 23.1%.
- Non-cash impairment charge of $488M ($337M after-tax) on Dr.Ci:Labo assets due to China market dynamics.
- FY24 outlook reaffirmed: net sales growth 1%-3%, organic growth 2%-4%, adjusted EPS $1.10-$1.20.
- Gross profit margin expanded 360 bps to 59.1%; adjusted gross margin expanded 410 bps to 61.6%.

## SEC filing metadata
- accession: 0001944048-24-000136
- form_type: 8-K
- ticker: KVUE
- cik: 0001944048
- company_name: Kenvue Inc.
- filed_at: 2024-08-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1944048/000194404824000136/0001944048-24-000136-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1944048/000194404824000136/kvue-20240806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001944048-24-000136
- JSON: https://secwatch.observer/filing/0001944048-24-000136.json
- Plain text: https://secwatch.observer/filing/0001944048-24-000136.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.